{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} The Detection of Axillary Adenopathy After a CoVID-19 Vaccine
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Learning Objectives
After completing this continuing education activity you will be able to:
- Identify the incidence of axillary lymphadenopathy from the Moderna and Pfizer-BioNTech COVID-19 vaccines.
- Explain recommendations from the Society of Breast Imaging (SBI) related to axillary lymphadenopathy detected on mammography.
Disclosures
The author(s), faculty, staff, and planners in any position in any position to control the content of this activity, have disclosed that they have no financial relationships with, or financial interests in, any commercial companies relevant to this educational activity.
Price:
$12.95
Credits:
- ANCC 1.0 CH
- DC - BON 1.0 CH
- FL - BON 1.0 CH
- GA - BON 1.0 CH
Lippincott Professional Development is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Test Code: OT0421
Published: April 2021
Expires: 3/7/2025
Sources:
Oncology Times
Required Passing Score: 8/10 (80%)